Evidence map›Paper›PMID 42875068›Full record

ReviewCanadian family physician Medecin de famille canadien2026

Implementing the 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable chronic obstructive pulmonary disease in primary care.

Anthony D D'Urzo, Lawrence D Jackson, Jean Bourbeau, Marie-France Beauchesne, Paul Hernandez, Don D Sin, Itamar E Tamari, Mohit Bhutani, Darcy D Marciniuk, Erika Penz and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian family physician Medecin de famille canadien, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anthony D D'UrzoAssociate Professor in the Department of Family and Community Medicine in the Temerty Faculty of Medicine, and UPLEARN Researcher at the University of Toronto in Ontario.
Lawrence D JacksonAdjunct Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto.
Jean BourbeauProfessor in the Department of Medicine, Director of the COPD Clinic and Pulmonary Rehabilitation, and Senior Scientist at the Research Institute of the McGill University Health Centre, all at McGill University in Montréal, Que.
Marie-France BeauchesneClinical Professor in the Faculté de pharmacie at the Université de Montréal in Quebec, and Associate Researcher, Le Centre de recherche du Centre hospitalier universitaire de Sherbrooke in Quebec.
Paul HernandezProfessor of Medicine at Dalhousie University in Halifax, NS, Head and Chief of the Division of Respirology at Nova Scotia Health and Dalhousie University, and Medical Director of the Pulmonary Rehabilitation Program at the Queen Elizabeth II Health Sciences Centre in Halifax.
Don D SinProfessor of Medicine and Director of the Centre for Heart Lung Innovation at the University of British Columbia in Vancouver.
Itamar E TamariFamily physician at Stonegate Community Health Centre in Toronto.
Mohit BhutaniProfessor in the Faculty of Medicine & Dentistry at the University of Alberta in Edmonton.
Darcy D MarciniukProfessor of Respirology, Critical Care, and Sleep Medicine, and Associate Vice-President of Research at the University of Saskatchewan in Saskatoon, and Medical Director of the LiveWell COPD Chronic Disease Management Program in the Saskatchewan Health Authority.
Erika PenzHead of the Division of Respirology, Critical Care, and Sleep Medicine at the University of Saskatchewan.
Joshua WaldAssociate Professor in the Department of Medicine, and Program Director of the Adult Respirology Training Program at McMaster University in Hamilton, Ont.
Ross E G UpshurDalla Lana Chair in Clinical Public Health, Head of the Division of Clinical Public Health, Associate Director of the Collaborative Centre for Climate, Health & Sustainable Care, and Professor in the Department of Family and Community Medicine in the Dalla Lana School of Public Health at the University of Toronto.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo increase family physician (FP) awareness of the 2023 Canadian Thoracic Society (CTS) guideline recommendations on pharmacotherapy in patients with stable chronic obstructive pulmonary disease (COPD) and self-efficacy in implementing the recommendations in primary care to achieve 3 high-priority patient outcomes. QUALITY OF EVIDENCE: Strength and certainty of pharmacotherapy recommendations is based on meta-analysis of evidence. The strength of recommendations ranges from weak to strong and certainty ranges from low to high. MAIN MESSAGE: Provider awareness and self-efficacy are 2 of the most employed strategies to facilitate guideline implementation. The 2023 CTS pharmacotherapy recommendations for the management of stable COPD are based on assessment of treatable traits including symptom burden, health status, and risk of exacerbations. Key pharmacotherapy recommendations include single long-acting bronchodilator (LABD) for patients with low symptom burden and mild health status impairment; dual long-acting bronchodilator for patients with moderate-to-high symptom burden and health status impairment but low risk for exacerbations; and single-inhaler triple therapy (over dual LABD or inhaled corticosteroid and long-acting β

conclusionVarious implementation strategies, including guideline awareness and provider self-efficacy, aim to reduce the gap between guidelines and real-world care. This synopsis aims to familiarize FPs with recommended pharmacotherapy in the context of stable COPD and gain the necessary confidence to apply the recommendations in their practices to alleviate symptoms, prevent exacerbations, and reduce mortality.

Indexed as

Bronchodilator AgentsPractice Guidelines as TopicPrimary Health CarePulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesCanadaHumansSocieties, MedicalAdrenal Cortex HormonesBronchodilator Agents

Identifiers

PMID42875068
PMCPMC13662810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.